Neuromuscular Disorders Therapeutics
1. Agamree patent expiration
Treatment: Treatment of duchenne muscular dystrophy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12201639 | CATALYST | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| US11382922 | CATALYST | Aqueous oral pharmaceutical suspension compositions |
Jul, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690853 | CATALYST | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
Mar, 2033
(7 years from now) | |
| US11471471 | CATALYST | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| US10857161 | CATALYST | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| US8334279 | CATALYST | Non-hormonal steroid modulators of NF-κB for treatment of disease |
May, 2029
(3 years from now) | |
| US11833159 | CATALYST | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
2. Amvuttra patent expiration
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
AMVUTTRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9399775 | ALNYLAM | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(6 years from now) | |
| US11286486 | ALNYLAM | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10683501 | ALNYLAM | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US9370581 | ALNYLAM | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US8828956 | ALNYLAM | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US10131907 | ALNYLAM | Glycoconjugates of RNA interference agents |
Aug, 2028
(2 years from now) | |
| US8106022 | ALNYLAM | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(3 years from now) | |
| US10612024 | ALNYLAM | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10208307 | ALNYLAM | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US12049628 | ALNYLAM | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10570391 | ALNYLAM | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(6 years from now) | |
| US11401517 | ALNYLAM | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10806791 | ALNYLAM | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| New Indication(I-964) | Mar 20, 2028 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Dosage: SOLUTION
More Information on Dosage
AMVUTTRA family patents
3. Evrysdi patent
expiration
Treatment: Treatment of spinal muscular atrophy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969754 | GENENTECH | Compounds for treating spinal muscular atrophy |
May, 2035
(9 years from now) | |
| US12122789 | GENENTECH | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
Apr, 2041
(15 years from now) | |
| US9586955 | GENENTECH | Compounds for treating spinal muscular atrophy |
Feb, 2033
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350273 | GENENTECH | Treatment Of Sma |
Oct, 2038
(12 years from now) | |
| US11534444 | GENENTECH | Treatment of SMA |
Oct, 2038
(12 years from now) | |
| US11827646 | GENENTECH | Compounds for treating spinal muscular atrophy |
Jan, 2036
(9 years from now) | |
| US11938136 | GENENTECH | Compositions for treating spinal muscular atrophy |
Nov, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 11 February, 2025
Dosage: TABLET; FOR SOLUTION
How can I launch a generic of EVRYSDI before it's drug patent expiration?
More Information on Dosage
EVRYSDI family patents
4. Firdapse patent expiration
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11274332 | CATALYST | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US11274331 | CATALYST | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US11268128 | CATALYST | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US11060128 | CATALYST | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US10793893 | CATALYST | Methods of administering 3,4-diaminopyridine |
May, 2034
(8 years from now) | |
| US10626088 | CATALYST | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| New Patient Population(NPP) | Sep 29, 2025 |
| Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Dosage: TABLET
How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage
FIRDAPSE family patents
5. Onpattro patent expiration
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
ONPATTRO's oppositions filed in EPO
ONPATTRO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9567582 | ALNYLAM | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8895721 | ALNYLAM | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8895718 | ALNYLAM | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8372968 | ALNYLAM | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8362231 | ALNYLAM | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8552171 | ALNYLAM | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(4 years ago) | |
| US11079379 | ALNYLAM | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(9 years from now) | |
| US10240152 | ALNYLAM | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US8168775 | ALNYLAM | Compositions and methods for inhibiting expression of transthyretin |
Aug, 2032
(6 years from now) | |
| US8334373 | ALNYLAM | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9193753 | ALNYLAM | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(4 years ago) | |
| US8778902 | ALNYLAM | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US9943539 | ALNYLAM | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(2 years ago) | |
| US9943538 | ALNYLAM | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(2 years ago) | |
| US8741866 | ALNYLAM | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US8802644 | ALNYLAM | Lipid formulation |
Oct, 2030
(4 years from now) | |
| US8822668 | ALNYLAM | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8158601 | ALNYLAM | Lipid formulation |
Nov, 2030
(4 years from now) | |
| US9364435 | ALNYLAM | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US9234196 | ALNYLAM | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US11141378 | ALNYLAM | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8642076 | ALNYLAM | Lipid containing formulations |
Oct, 2027
(1 year, 7 months from now) | |
| US8492359 | ALNYLAM | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8058069 | ALNYLAM | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| M(M-270) | Jan 13, 2026 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Dosage: SOLUTION
More Information on Dosage
ONPATTRO family patents
6. Tegsedi patent expiration
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
TEGSEDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA | Gapped oligonucleotides |
Mar, 2023
(2 years ago) | |
| US7101993 | AKCEA | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US9061044 | AKCEA | Modulation of transthyretin expression |
Apr, 2031
(5 years from now) | |
| US8101743 | AKCEA | Modulation of transthyretin expression |
Apr, 2025
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA | Modulation of transthyretin expression |
Apr, 2031
(5 years from now) | |
| US8697860 | AKCEA | Diagnosis and treatment of disease |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Dosage: SOLUTION
More Information on Dosage
TEGSEDI family patents
7. Viltepso patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
VILTEPSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(5 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity(ODE-280) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: 12 August, 2024
Market Authorisation Date: 12 August, 2020
Dosage: SOLUTION
More Information on Dosage
VILTEPSO family patents
8. Vyondys 53 patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
VYONDYS 53's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10227590 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US10968450 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US9024007 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US10421966 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US9994851 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10266827 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| USRE47691 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2028
(2 years from now) | |
| US10995337 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents
9. Zilbrysq patent expiration
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10208089 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US10106579 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US11014965 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US10435438 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US10562934 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752190 | UCB | Modulators of complement activity |
Jun, 2035
(9 years from now) | |
| US10835574 | UCB | Modulators of complement activity |
Jun, 2035
(9 years from now) | |
| US11965040 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US11535650 | UCB | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
Drugs and Companies using ZILUCOPLAN SODIUM ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Dosage: SOLUTION
More Information on Dosage
ZILBRYSQ family patents